Environmental Risk Assessments (ERA) for Roche's Active Pharmaceutical Ingredients (API)

Sustainability Download Centre

Date
2022/10
2022/10
2022/09
2021/05
2021/05
2021/05
2021/05
2021/05
2021/05
2021/05
2021/05
2021/05
2021/06
2021/06
2021/06
2021/06
2021/06
2021/06
2021/06
2021/06
2021/06
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2021/08
2022/06
2021/10
2021/10
2021/10
2021/10
2021/10
2021/11
2021/11
2021/11
2021/11
2021/12
2022/06
2022/06
2022/06
Title
Vabysmo - Faricimab
Xofluza - Baloxavir marboxil
Gavreto - Ralsetinib
Alecensa - Alectinib
Cellcept - Mycophenolate mofetil
Copegus - Ribavirin
Cotellic - Cobimetinib
Erivedge - Vismodegib
Esbriet - Pirfenidone
Evrysdi - Risdiplam
Madopar - Benserazide
Madopar - Levodopa
Enspryng - Satralizumab
Invirase - Saquinavir mesylate
Mircera - C.E.R.A.
Pegasys - Peginterferon a-2a
Rocephin - Lidocaine
Tamiflu - Oseltamivir
Tarceva – Erlotinib
Xeloda - Capecitabine
Zelboraf - Vemurafenib
Avastin - Bevacizumab
Fuzeon - Enfuvirtide
Gazyvaro - Obinutuzumab
Hemlibra - Emicizumab
Herceptin - Trastuzumab
Lucentis - Ranibizumab
MabThera - Rituximab
NeoRecormon - Epoetin Beta
Ocrevus - Ocrelizumab
Perjeta - Pertuzumab
Pulmozyme - Dornase alfa
Roferon-A - Interferon alfa-2a
Rozlytrek - Entrectinib
Tecentriq- Atezolizumab
Rocephin - Ceftriaxone
Bondronat - Ibandronate
Bonviva - Ibandronate
Rivotril - Clonazepam
Valcyte - Valganciclovir
Valium - Diazepam
Kadcyla - Trastuzumab emtansine
Polivy - Polatuzumab vedotin
Roaccutane - Isotretinoin
Ronapreve - Casirivimab + Imdevimab
Actemra/RoActemra - Tocilizumab
Bactrim - Trimethoprim
Bactrim - Sulfamethoxazole
Lunsumio - Mosunetuzumab
Type
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA
ERA

The publication of environmental risk assessment (ERA) summaries is part of Roche’s engagement on developing a better understanding of issues regarding pharmaceuticals in the environment (PiE). New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.

Downloads

Discover more